Mesoblast Ltd
ASX:MSB
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.26
3.05
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Mesoblast Ltd
Mesoblast Ltd
Cash Taxes Paid
Mesoblast Ltd
Cash Taxes Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Taxes Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mesoblast Ltd
ASX:MSB
|
Cash Taxes Paid
$4k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immutep Ltd
ASX:IMM
|
Cash Taxes Paid
AU$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Cash Taxes Paid
$784m
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Cash Taxes Paid
-AU$15.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Cash Taxes Paid
-AU$10.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Cash Taxes Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Mesoblast Ltd
Glance View
Mesoblast Ltd., a biotechnology company based in Australia, is navigating the frontier of regenerative medicine with its innovative approach to cell therapy. Founded in 2004, Mesoblast has carved a niche for itself by concentrating on the development and commercialization of allogeneic cellular medicines derived from mesenchymal lineage adult stem cells. These stem cells are pivotal in regenerative therapy due to their remarkable ability to differentiate, reduce inflammation, and promote tissue repair. Mesoblast harnesses this potential to address critical medical conditions, including cardiovascular diseases, spine diseases, immune-mediated diseases, and some rare pediatric conditions. By developing proprietary technology, the company aims to produce off-the-shelf therapies that can be readily available to patients, avoiding the complexities and delays often associated with personalized cellular therapies. The company’s revenue model hinges on the development of its extensive pipeline of products, with an eye towards capturing significant market opportunities across multiple therapeutic areas. Revenues are primarily anticipated from three avenues: collaborations with major pharmaceutical companies, licensing agreements, and, eventually, product sales upon regulatory approval. Mesoblast's strategic partnerships often involve substantial upfront payments, milestone payments, and royalties on the sale of licensed products. For instance, collaborations with giants like Grunenthal in Europe have fortified its research and funding capabilities. Meanwhile, Mesoblast is also committed to expanding its product commercialization capabilities to strategically manage its transition from a research-centered entity to a biopharmaceutical pioneer with marketed therapies. This dual-focused strategy aspires to deliver shareholder value while advancing the horizons of medical treatment.
See Also
What is Mesoblast Ltd's Cash Taxes Paid?
Cash Taxes Paid
4k
USD
Based on the financial report for Jun 30, 2024, Mesoblast Ltd's Cash Taxes Paid amounts to 4k USD.
What is Mesoblast Ltd's Cash Taxes Paid growth rate?
Cash Taxes Paid CAGR 1Y
-80%
Over the last year, the Cash Taxes Paid growth was -80%.
You don't have any saved screeners yet
